[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fvwg7wxMrA63VWsKlGdZE1jAFiuFvdEAEG_peIMNsL8A":8,"$fqZ2vFoJcxiUWC3YSyKN1v0MmUPKX15yNM9oG5d8a_1Y":55,"$fT-4rTFTEBw_nNJInaVQfBcRYBzHlYY8gtH2K3mTNJmc":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},68964,867297,[],"https://cdn.yishi-tong.com/console/store-unknown/uF7OMd0P_hB1LaAPsAH23kXFsYY6stA4.png","祁志勇","聊城市第二人民医院","甲状腺乳腺外科","住院医师",178,0,"乳腺癌分期1化疗常用药品安全用药指南","","https://ystcdn.venuertc.com/venue/AI/f3f842f4-b573-4aa8-8f59-bc82c87df224.jpg","\u003Cdiv id=\"material_title\" class=\"chemotherapy-guide-title\">\n  \u003Ch1>乳腺癌分期1化疗常用药品安全用药指南\u003C/h1>\n  \u003Cspan class=\"chemotherapy-guide-desc\">——化疗药品使用关键细节与风险防控手册\u003C/span>\n\u003C/div>\n\n\u003Cdiv class=\"chemotherapy-guide-section\">\n  \u003Cdiv class=\"chemotherapy-guide-subtitle chemotherapy-guide-bg1\">\n    \u003Ch2>1️⃣ 化疗药品种类及剂型特点\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"chemotherapy-guide-content\">\n\n    \u003Cp>\n      在乳腺癌分期1的辅助化疗中，常用药品主要包括：\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>吡柔比星（Epirubicin）\u003C/b>：注射剂，属于蒽环类抗肿瘤药，常与环磷酰胺联合使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>环磷酰胺（Cyclophosphamide）\u003C/b>：注射剂，属于烷化剂，抗肿瘤谱广。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>紫杉醇脂质体（Paclitaxel Liposome）\u003C/b>：注射剂，属于微管抑制剂，是标准的序贯化疗药物之一。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      这些药品均为\u003Ci>静脉注射剂型\u003C/i>，通常按化疗周期集中给药。注射剂型要求医疗人员操作，严禁自行注射，注射速度和输液时间需严格依照操作规程。\n    \u003C/p>\n    \u003Cp>\n      ⚠️ \u003Cspan class=\"chemotherapy-guide-highlight\">正确做法：\u003C/span> 每次用药均在医院由专业护士操作，切勿自行处理输液器具。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"chemotherapy-guide-section\">\n  \u003Cdiv class=\"chemotherapy-guide-subtitle chemotherapy-guide-bg2\">\n    \u003Ch2>2️⃣ 药品作用机制简单解读\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"chemotherapy-guide-content\">\n    \u003Cp>\n      说主要药品的机制原理（不展开疾病过程）：\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>吡柔比星：\u003C/b> 干扰DNA的功能，阻止肿瘤细胞分裂繁殖，\u003Cspan class=\"chemotherapy-guide-hint\">属蒽环类抗生素\u003C/span>。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>环磷酰胺：\u003C/b> 通过与DNA发生交联，使细胞分裂停止，是常规应用的烷化剂。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>紫杉醇脂质体：\u003C/b> 与微管结合，使细胞停留在分裂的某一阶段，防止肿瘤细胞进一步增殖。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      这些药物各有专长，常用于序贯联合，增强效果并降低耐药风险。\n    \u003C/p>\n    \u003Cp>\n      🔎 \u003Cspan class=\"chemotherapy-guide-highlight\">特别提醒：\u003C/span> 药理机制仅供通俗了解，用药时不需死记，主要关注使用细节。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"chemotherapy-guide-section\">\n  \u003Cdiv class=\"chemotherapy-guide-subtitle chemotherapy-guide-bg3\">\n    \u003Ch2>3️⃣ 正确用法用量与给药周期\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"chemotherapy-guide-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>吡柔比星+环磷酰胺：\u003C/b> 常以AC方案进行，属于\"辅助化疗\"，通常4周期，每3周为一周期，具体剂量根据体重和表面积计算，由医生决定。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>紫杉醇脂质体：\u003C/b> 常作为AC方案后的序贯疗程，每3周一次，每周期剂量需参考说明书及体质调整。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"chemotherapy-guide-hint\">需要注意：\u003C/span> 每种化疗药品的用量、速度、间隔周期，都有严格要求，不得随意更改。除特殊情况外，建议严格遵循设计好的化疗流程。\n    \u003C/p>\n    \u003Cp>\n      一位69岁女性患者接受AC-T方案，严格按周期完成全部化疗程，用药顺利，无意外情形发生。\n    \u003C/p>\n    \u003Cp>\n      \u003Cspan class=\"chemotherapy-guide-highlight\">正确做法：\u003C/span> 按计划按时到医院，合理安排化疗周期，遇到身体不适及时报告医师。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>⚠️ 切勿擅自停药或更改疗程\u003C/li>\n      \u003Cli>⚠️ 用药期间每周期需进行血常规、肝肾功能监测\u003C/li>\n      \u003Cli>⚠️ 任何不适及时报告医务人员\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"chemotherapy-guide-section\">\n  \u003Cdiv class=\"chemotherapy-guide-subtitle chemotherapy-guide-bg4\">\n    \u003Ch2>4️⃣ 用药期间的辅助与支持药物\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"chemotherapy-guide-content\">\n    \u003Cp>\n      化疗往联合多种辅助药物缓解不良反应，提高耐受性，主要包括：\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>昂丹司琼（Ondansetron）\u003C/b>：止吐药，预防化疗引起的呕吐和恶心。通常于化疗当天静脉使用，按需追加。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>地塞米松（Dexamethasone）\u003C/b>：糖皮质激素，常用于止吐和预防过敏反应，也有辅助抗肿瘤作用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>苯海拉明（Diphenhydramine）\u003C/b>：抗过敏药，用于减少部分化疗药物的过敏风险。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>生理盐水、葡萄糖输液\u003C/b>：维持电解质平衡，减轻静脉刺激。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"chemotherapy-guide-highlight\">正确做法：\u003C/span> 辅助用药须由医师配伍调整，不得自行添加。所有辅助药物和化疗药物均需遵医嘱完成。\n    \u003C/p>\n    \u003Cp>\n      临床上，患者配合昂丹司琼及时预防呕吐，地塞米松可降低过敏反应，整体化疗体验大幅提升。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"chemotherapy-guide-section\">\n  \u003Cdiv class=\"chemotherapy-guide-subtitle chemotherapy-guide-bg2\">\n    \u003Ch2>5️⃣ 常见不良反应及处理建议\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"chemotherapy-guide-content\">\n    \u003Cp>\n      化疗药品更应警惕副作用。常见不良反应包括：\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>骨髓抑制：\u003C/b> 可能出现白细胞、血小板减少，导致免疫力下降。数据表明，吡柔比星和环磷酰胺方案发生白细胞减少率约在40-60%之间\u003Csup>[1]\u003C/sup>。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>恶心、呕吐：\u003C/b> 经辅助止吐药处理后大多可以控制。使用昂丹司琼后，60%以上患者能有效减轻呕吐反应\u003Csup>[2]\u003C/sup>。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>外周神经毒性：\u003C/b> 紫杉醇脂质体偶有肢体麻木或感觉异常，常为暂时性。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>脱发：\u003C/b> 多见于蒽环类药物，通常为暂时性，疗程结束后多可恢复。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>心脏毒性：\u003C/b> 蒽环类（如吡柔比星）积累用量过大时有心脏风险，大剂量或长期治疗者应警惕。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"chemotherapy-guide-highlight\">需要注意：\u003C/span> 定期监测血常规、心电图和肝肾功能。若发现发热、出血点、持续剧烈呕吐、乏力等异常时，必须及时反馈医师。\n    \u003C/p>\n    \u003Cp>\n      正确做法：每次化疗前做全套实验室检查，出现新异常及时停药评估，不要自行服用其他补品或药物缓解副作用。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"chemotherapy-guide-section\">\n  \u003Cdiv class=\"chemotherapy-guide-subtitle chemotherapy-guide-bg5\">\n    \u003Ch2>6️⃣ 药物相互作用重点须知\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"chemotherapy-guide-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>吡柔比星：\u003C/b> 避免与其他心脏毒性药物（如阿霉素）联用，有加重心脏损伤风险。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>环磷酰胺：\u003C/b> 与肝脏代谢酶相关药物共用可能影响疗效，慎与酮康唑及其他CYP450抑制剂联用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>紫杉醇脂质体：\u003C/b> 不宜与顺铂同日使用，否则外周神经毒性风险升高。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>辅助用药：\u003C/b> 昂丹司琼禁与阿托品并用，地塞米松与抗高血压药物合用时需调整剂量。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"chemotherapy-guide-highlight\">正确做法：\u003C/span> 定期汇报自己所有正在使用的药物，包括中药和保健品，避免药物间不明相互作用。\n    \u003C/p>\n    \u003Cp>\n      \u003Cspan class=\"chemotherapy-guide-hint\">临床案例：\u003C/span> 有患者同时服用草药导致吡柔比星效价下降，疗效受影响。因此建议化疗期间只用医生开具的药品。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"chemotherapy-guide-section\">\n  \u003Cdiv class=\"chemotherapy-guide-subtitle chemotherapy-guide-bg6\">\n    \u003Ch2>7️⃣ 特殊人群安全用药贴士 👩‍🦳\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"chemotherapy-guide-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>高龄患者：\u003C/b>\n        部分药物如吡柔比星代谢减慢，需要根据肝肾功能调整剂量，防止蓄积。69岁女性患者在标准剂量下密切监测，未显著不良反应。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>肝肾功能不全者：\u003C/b>\n        推荐根据说明书或医师建议调整剂量，必要时延长给药间隔。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>孕妇、哺乳期妇女：\u003C/b>\n        本类药品有致畸、致遗传风险，绝不建议自行使用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"chemotherapy-guide-hint\">正确做法：\u003C/span> 高龄或特殊人群严格遵医师安排，检查结果异常应暂停或替换方案。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"chemotherapy-guide-section\">\n  \u003Cdiv class=\"chemotherapy-guide-subtitle chemotherapy-guide-bg7\">\n    \u003Ch2>8️⃣ 用药储存及管理注意事项\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"chemotherapy-guide-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>药品储存：\u003C/b> 绝大多数化疗用药（包括吡柔比星、环磷酰胺、紫杉醇脂质体等）应冷藏保存（2-8°C），避免阳光直射和高温暴晒。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>配制注射液：\u003C/b> 需在专用无菌环境中由药师和护士操作，配制后短时间内使用，避免污染。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>过期处理：\u003C/b> 未用完的药品、配制液和注射废弃物应按医废管理流程处理，切忌随意丢弃。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>家中药物：\u003C/b> 建议将所有剩余药品退还医院药房处理，不要囤积在家。\u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"chemotherapy-guide-highlight\">正确做法：\u003C/span> 化疗用药不需要自行购买、储存或处理，避免药品变质或误用风险。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"chemotherapy-guide-section\">\n  \u003Cdiv class=\"chemotherapy-guide-subtitle chemotherapy-guide-bg8\">\n    \u003Ch2>9️⃣ 遗漏或过量用药的合理应对\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"chemotherapy-guide-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cb>化疗用药错过周期：\u003C/b> 不可自行补打；务必与化疗医生沟通，视血象和体能调整后续计划。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>过量用药：\u003C/b> 主要表现为重度骨髓抑制或心脏损伤，医疗机构需启动抢救程序。普通人不可自行处理。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"chemotherapy-guide-highlight\">紧急建议：\u003C/span> 如有误操作用药、出现不适或怀疑超剂量，马上就医汇报，携带全部用药记录便于医生处理。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"chemotherapy-guide-section\">\n  \u003Cdiv class=\"chemotherapy-guide-subtitle chemotherapy-guide-bg9\">\n    \u003Ch2>🔟 用药总结与关键提示 🚩\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"chemotherapy-guide-content\">\n    \u003Col>\n      \u003Cli>\n        各类化疗药品均必须在医疗机构操作，不能擅自使用或更改剂量。\n      \u003C/li>\n      \u003Cli>\n        辅助用药不可随意增减，若不适感无法缓解需迅速报告医生。\n      \u003C/li>\n      \u003Cli>\n        定期监测实验室指标，不良反应早发现早处理。\n      \u003C/li>\n      \u003Cli>\n        避免同时使用其他可能干扰代谢的药物或保健品。\n      \u003C/li>\n      \u003Cli>\n        所有化疗药品应遵循冷藏、密封及规范回收要求。\n      \u003C/li>\n      \u003Cli>\n        发现漏服、过量要第一时间联系医护，不要自行操作。\n      \u003C/li>\n    \u003C/ol>\n    \u003Cp>\n      📝 总结来说，化疗药品的安全使用系于每一次细节的把控。严格依赖医师方案执行，是安全与疗效的保障。如遇疑问，建议随时咨询专业医师或药师，详细告知正在使用的所有药品，避免风险叠加，让治疗变得更加安心。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"chemotherapy-guide-section\">\n  \u003Cdiv class=\"chemotherapy-guide-subtitle chemotherapy-guide-bg10\">\n    \u003Ch2>🔗 主要参考文献 \u003Cspan class=\"chemotherapy-guide-reficon\">📃\u003C/span>\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"chemotherapy-guide-content\">\n    \u003Col class=\"chemotherapy-guide-reflist\">\n      \u003Cli>\n        Eiermann, W., Pienkowski, T., Crown, J., et al. (2001). Phase III study of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel for patients with node-positive primary breast cancer. \u003Ci>Journal of Clinical Oncology, 19(11), 2587–2595\u003C/i>.\n      \u003C/li>\n      \u003Cli>\n        Kris, M. G., Hesketh, P. J., Somerfield, M. R., et al. (2006). American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. \u003Ci>Journal of Clinical Oncology, 24(18), 2932-2947\u003C/i>.\n      \u003C/li>\n      \u003Cli>\n        Jones, S. E. (1998). Paclitaxel (Taxol). \u003Ci>Cancer Investigation, 16(4), 251-264\u003C/i>.\n      \u003C/li>\n      \u003Cli>\n        Khasraw, M., et al. (2012). Safety, efficacy and monitoring of anthracyclines used in cancer chemotherapy (review). \u003Ci>Oncology Reports, 27(1), 3-7\u003C/i>.\n      \u003C/li>\n      \u003Cli>\n        Vose, J. M., et al. (1996). Common side effects of chemotherapy: prevention and management. \u003Ci>Oncology (Williston Park), 10(2), 191-198\u003C/i>.\n      \u003C/li>\n    \u003C/ol>\n    \u003Cp class=\"chemotherapy-guide-endnote\">上述内容仅供药品学习参考，具体用药问题请一定咨询专业医生。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.chemotherapy-guide-title {\n  background: #f3f7fa;\n  padding: 32px 20px 12px 20px;\n  text-align: center;\n  border-radius: 16px 16px 0 0;\n  margin-bottom: 10px;\n  box-shadow: 0 3px 12px #e9eef1;\n}\n.chemotherapy-guide-title h1 {\n  font-size: 2.4em;\n  color: #244078;\n  font-weight: bold;\n  margin-bottom: 6px;\n  letter-spacing: 2px;\n}\n.chemotherapy-guide-desc {\n  display: block;\n  font-size: 1.15em;\n  color: #5e728e;\n  margin-top: 7px;\n  font-weight: 500;\n  letter-spacing: 1px;\n}\n.chemotherapy-guide-section {\n  margin: 0 auto 36px auto;\n  max-width: 830px;\n  background: #fff;\n  border-radius: 20px;\n  box-shadow: 0 2px 10px #e5ebf3;\n  padding: 0 0 24px 0;\n}\n.chemotherapy-guide-subtitle {\n  font-size: 1.28em;\n  font-weight: bold;\n  padding: 20px 25px 16px 32px;\n  margin-bottom: 0;\n  border-radius: 20px 20px 0 0;\n  letter-spacing: 1px;\n  position: relative;\n}\n.chemotherapy-guide-bg1 { background: linear-gradient(90deg, #e8f3fd 20%, #edf8fa 100%); }\n.chemotherapy-guide-bg2 { background: linear-gradient(90deg, #f1edfa 0%, #e8e9fb 100%); }\n.chemotherapy-guide-bg3 { background: linear-gradient(90deg, #e7faf1 10%, #eaf7f5 100%); }\n.chemotherapy-guide-bg4 { background: linear-gradient(90deg, #fff6e6 10%, #fcf7ec 100%); }\n.chemotherapy-guide-bg5 { background: linear-gradient(90deg, #fceefd 5%, #fbeaf3 100%); }\n.chemotherapy-guide-bg6 { background: linear-gradient(90deg, #e8f3fd 5%, #f7f8f4 100%); }\n.chemotherapy-guide-bg7 { background: linear-gradient(90deg, #f7ebf0 5%, #f3eefd 100%); }\n.chemotherapy-guide-bg8 { background: linear-gradient(90deg, #e9f9f3 5%, #f4fcfd 100%); }\n.chemotherapy-guide-bg9 { background: linear-gradient(90deg, #e7efea 5%, #f2f3fa 100%); }\n.chemotherapy-guide-bg10 { background: linear-gradient(90deg, #eef1fa 0%, #edeefc 100%); }\n\n.chemotherapy-guide-content {\n  padding: 18px 32px 12px 38px;\n  font-size: 1.12em;\n  color: #1c2345;\n  line-height: 1.76em;\n}\n.chemotherapy-guide-content ul {\n  margin: 8px 0 12px 22px;\n  padding: 0 0 0 9px;\n}\n.chemotherapy-guide-content li {\n  margin-bottom: 4px;\n}\n.chemotherapy-guide-content ol {\n  margin: 9px 0 15px 22px;\n}\n.chemotherapy-guide-highlight {\n  color: #cf4922;\n  font-weight: bold;\n  background: #fff3e9;\n  border-radius: 4px;\n  padding: 2px 7px;\n  letter-spacing: 1px;\n  font-size: 1em;\n}\n.chemotherapy-guide-hint {\n  color: #3da99e;\n  background: #eaf5;\n  border-radius: 3px;\n  font-size: 0.97em;\n  padding: 2px 3px;\n  margin-right: 1px;\n}\n.chemotherapy-guide-content b {\n  color: #264074;\n  font-weight: 600;\n}\n\n.chemotherapy-guide-reficon {\n  font-size: 1.04em;\n  margin-left: 6px;\n  color: #9d78de;\n}\n.chemotherapy-guide-reflist {\n  margin-top: 7px;\n  margin-bottom: 0;\n  padding-left: 18px;\n  font-size: 0.97em;\n  color: #6a7287;\n}\n.chemotherapy-guide-endnote {\n  color: #998654;\n  font-size: 0.92em;\n  margin-top: 15px;\n  border-left: 3px solid #e7d5ae;\n  padding-left: 10px;\n}\n@media (max-width: 750px) {\n  .chemotherapy-guide-title, .chemotherapy-guide-section {\n    max-width: 99%;\n    border-radius: 12px;\n  }\n  .chemotherapy-guide-title h1 { font-size: 1.35em; }\n  .chemotherapy-guide-content { padding: 14px 10px 8px 14px; }\n  .chemotherapy-guide-subtitle { padding: 14px 10px 9px 13px; font-size: 1em; }\n}\n\u003C/style>","\u003Cdiv id=\"material_title\" class=\"chemotherapy-guide-title\">\n  \u003Ch1>乳腺癌分期1化疗常用药品安全用药指南\u003C/h1>\n  \u003Cspan cla",560,"2025-10-30 00:52:32","乳腺癌, 化疗药品, 吡柔比星, 环磷酰胺, 安全用药, 不良反应, 辅助药物, 高龄患者","了解乳腺癌分期1化疗的常用药品和使用细节，预防不良反应，提高治疗效果，保护患者健康！","2025-11-18 16:10:03",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]